Yuan Fen, Wu Wenbin, Ma Leyi, Wang Dingkun, Hu Meilin, Gong Jing, Fang Ke, Xu Lijun, Dong Hui, Lu Fuer
Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei 430030, China.
Institution of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, HuaZhong University of Science and Technology, Wuhan, Hubei 430030, China.
Pharmacol Res. 2022 Mar;177:106121. doi: 10.1016/j.phrs.2022.106121. Epub 2022 Feb 7.
Metabolic diseases are globally popular, and a systematic review and meta-analysis of turmeric and curcuminoids on glucose metabolism among people with metabolic diseases was performed.
We comprehensively searched Web of Science, PubMed, Ovid (including EMBASE and MEDLINE), Scopus, the Cochrane Library and two Chinese databases, Wanfang and CNKI for RCTs that focused on the effects of turmeric and curcuminoids on fasting blood glucose (FBG), hemoglobin A1C (HbA1c), fasting serum insulin (FSI) and HOMA-IR among patients with metabolic diseases. The FBG and HbA1c were the main outcomes to be analyzed. With random-effects models, separate meta-analyses were conducted by inverse-variance and reported as WMD with 95% CIs.
Evidence from 17 RCTs including 22 trials showed that turmeric and curcuminoids lowered FBG by - 7.86 mg/dL (95% CI: -12.04, -3.67 mg/dL; P = 0.0002), HbA1c by - 0.38% (95% CI: -0.52%, -0.23%; P < 0.00001) and HOMA-IR by - 1.01 (95% CI: -1.6, -0.42; P = 0.0008). Moreover, they decreased fasting serum insulin by - 1.69 mU/L (95% CI: -3.22, -0.16 mU/L; P = 0.03) after more than 8 weeks of intervention in a subgroup analysis.
Turmeric and curcuminiods decrease FBG, HbA1c and HOMA-IR significantly among subjects with metabolic disease. Additionally, they may have an effect on FSI concentrations if the intervention period is more than 8 weeks. However, attention should be paid to these outcomes due to the significant heterogeneity.
代谢性疾病在全球范围内广泛流行，我们对姜黄和姜黄素类化合物对代谢性疾病患者糖代谢的影响进行了系统评价和荟萃分析。
我们全面检索了Web of Science、PubMed、Ovid（包括EMBASE和MEDLINE）、Scopus、Cochrane图书馆以及两个中文数据库万方和知网，以查找关注姜黄和姜黄素类化合物对代谢性疾病患者空腹血糖（FBG）、糖化血红蛋白（HbA1c）、空腹血清胰岛素（FSI）和胰岛素抵抗指数（HOMA-IR）影响的随机对照试验（RCT）。FBG和HbA1c是主要分析指标。采用随机效应模型，通过逆方差法进行单独的荟萃分析，并以加权均数差（WMD）及95%可信区间（CI）报告结果。
来自17项RCT（包括22项试验）的证据表明，姜黄和姜黄素类化合物可使FBG降低7.86mg/dL（95%CI：-12.04，-3.67mg/dL；P=0.0002），HbA1c降低0.38%（95%CI：-0.52%，-0.23%；P<0.00001），HOMA-IR降低1.01（95%CI：-1.6，-0.42；P=0.0008）。此外，在亚组分析中，经过超过8周的干预后，它们可使空腹血清胰岛素降低1.69mU/L（95%CI：-3.22，-0.16mU/L；P=0.03）。
姜黄和姜黄素类化合物可显著降低代谢性疾病患者的FBG、HbA1c和HOMA-IR。此外，如果干预时间超过8周，它们可能对FSI浓度有影响。然而，由于存在显著异质性，对这些结果应予以关注。
